Vol.53 No.11 November 2005
Results of a post-marketing clinical trial of teicoplanin in renal dysfunction patients -Study of efficacy and safety
1)Division of Artificial Dialysis and Nephrology, Kinki University Hospital, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, Japan
2)Division of Internal Medicine, Shinrakuen Hospital
Abstract
We studied the efficacy and safety of teicoplanin (TEIC) in renal dysfunction patients with MRSA infection, and the validity of the recommended dosage regimens as related to the degree of renal function, that are currently recommended for use.
23 patients were examined, and the safety rate was 80.0% (16/20), excluding three non-evaluable patients from the group used for evaluation. The efficacy rate was 72.2% (13/18) , after excluding two non-evaluable patients, and 90.9% (10/11) in the group on a daily dosage of 400 mg, and 3/7 in the group on a daily dosage of 200 mg. In the patient group with Ccr≤10, including dialysis patients, the trough serum level concentration, which is important to judge efficacy, had decreased greatly by the ninth day compared with other groups.
We conclude that the dosage interval for TEIC in the patient group with Ccr>10 is appropriate, and a daily dosage of 400 mg is preferable. This study also showed the necessity for reexamination of the dosage interval in patients with Ccr≤10, including dialysis patients.
Key word
teicoplanin, renal dysfunction, dialysis, serum concentration, safety
Received
September 12, 2005
Accepted
October 19, 2005
Jpn. J. Chemother. 53 (11): 686-695, 2005
